Preclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/in Preclinical Research/by MaxA New Wave in Bone Grafting: Coral-Inspired Material Offers Hope for Faster Healing
/in Preclinical Research/by MaxAPVO442: A Promising New Bispecific Antibody for Prostate Cancer Treatment
/in Preclinical Research/by MaxInhibition of SREBP Reinduces Docetaxel Sensitivity in Advanced Prostate Cancer
/in Preclinical Research/by MaxKaempferol: A Potential Treatment for Emotional Stress-Aggravated Prostate Cancer Metastasis
/in Preclinical Research/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 30/2026 July 26, 2026
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026